{"id":"NCT00912093","sponsor":"Shire","briefTitle":"A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)","officialTitle":"A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Icatibant for Subcutaneous Injection in Patients With Acute Attacks of Hereditary Angioedema (HAE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07-16","primaryCompletion":"2010-10-01","completion":"2010-10-01","firstPosted":"2009-06-03","resultsPosted":"2014-08-06","lastUpdate":"2021-06-11"},"enrollment":98,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hereditary Angioedema"],"interventions":[{"type":"DRUG","name":"Icatibant","otherNames":["Firazyr"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Icatibant","type":"EXPERIMENTAL"}],"summary":"This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).","primaryOutcome":{"measure":"Time to Onset of Symptom Relief for an Acute Attack, as Assessed by the Patient","timeFrame":"Up to 120 hours post-dose","effectByArm":[{"arm":"Randomized-Icatibant (Blinded Treatment)--Non-laryngeal","deltaMin":2,"sd":null},{"arm":"Randomized-Placebo (Blinded Treatment)-Non-laryngeal","deltaMin":19.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":64,"countries":["United States","Australia","Canada","Hungary","Israel","Romania","Russia","South Africa","Ukraine"]},"refs":{"pmids":["26556097","25198193","23167682","22123383"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["Hereditary angioedema","Headache","Upper Respiratory Tract Infection"]}}